Best Hospitals for Ovarian Cancer Treatment in Chennai, India

Ovarian cancer is the most lethal gynaecological malignancy, primarily because over 70% of cases are diagnosed at FIGO Stage III or IV, when the disease has disseminated beyond the pelvis into the peritoneal cavity and, less commonly, to distant organs. The three principal histological subtypes are epithelial ovarian carcinoma (accounting for ~90% of cases, with high-grade serous carcinoma being the most common and aggressive variant), germ cell tumours (more common in younger women, with generally better prognosis), and sex cord-stromal tumours. The disease causes progressive abdominal distension, ascites, bowel dysfunction, and systemic cachexia by compressing and infiltrating pelvic and abdominal structures; BRCA1/BRCA2 germline mutations confer a lifetime risk of 40–60% and are pivotal in treatment planning.

• ELIGIBLE PATIENTS:
• Women with confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma at any FIGO stage seeking curative or optimal cytoreductive surgery
• Patients with germ cell or sex cord-stromal ovarian tumours requiring fertility-sparing or radical surgery
• Patients with BRCA1/BRCA2 mutations or HRD-positive tumours who are candidates for PARP inhibitor maintenance therapy
• Patients with recurrent platinum-sensitive ovarian cancer eligible for secondary cytoreduction (DESKTOP III criteria: ECOG 0–1, complete resection at first surgery, no ascites)
• +20 more

Surgical APPROACHES:

1. Primary Cytoreductive Surgery (Upfront Debulking): The gold standard for resectable Stage III–IV ovarian cancer. Performed by a gynaecological oncologist, it includes total hysterectomy, bilateral salpingo-oophorectomy (BSO), infracolic omentectomy, pelvic and para-aortic lymphadenectomy, peritoneal stripping, and, where necessary, bowel resection with primary anastomosis, diaphragm stripping/resection, splenectomy, or cholecystectomy. The surgical goal is R0 resection — no macroscopic residual tumour — which is the single strongest predictor of survival in advanced ovarian cancer.

2. Fertility-Sparing Surgery: For Stage IA Grade 1–2 epithelial cancers or germ cell tumours in women of reproductive age: unilateral salpingo-oophorectomy with comprehensive surgical staging (peritoneal biopsies, omentectomy, lymph node sampling), preserving the contralateral ovary and uterus.

3. Robotic-Assisted Laparoscopic Surgery (da Vinci System): Available at premier oncology centres in India (Tata Memorial, Apollo, Manipal) and the UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai). Robotic platforms offer 3D visualisation, articulated wristed instruments (EndoWrist technology), and tremor filtration, enabling precise dissection in the pelvis and para-aortic region with reduced blood loss (<200 mL vs ~400–600 mL open), shorter hospital stay (4–6 days vs 7–10 days), and faster return to chemotherapy. Best suited for early-stage disease and interval debulking after NACT.

PHASE 1 — REMOTE PRE-CONSULTATION (Week 1–2, from home country):

• Patient submits medical records, imaging (CT/PET-CT), pathology reports, and biomarker results to GAF Healthcare's oncology coordination team.
• Remote tumour board review conducted by gynaecological oncologist and medical oncologist at the receiving institution.
• GAF Healthcare provides a written Treatment Roadmap: proposed surgical approach, chemotherapy protocol, estimated duration of stay, and itemised cost estimate.
• e-Medical visa application initiated for India (typically 3–5 business days approval); UAE tourist/medical visa or visa-on-arrival processed per patient nationality.

PHASE 2 — ARRIVAL & PRE-OPERATIVE WORKUP (Days 1–3 in country):